During the current grant period, CCSG developmental funds were used to support the mission of the Cancer Center in 2 categories critical to the advancement of its goals: 1) additional faculty recruitment in disciplines related to the strategic vision of the Center and 2) pilot project grants to stimulate cross-disciplinary research involving population science. Both categories have proven rich opportunities for the Center to strengthen and diversify its research portfolio. Funds requested to support faculty recruitment in strategic areas have enabled the Center to attract top talent by providing a start-up/transition package that has enabled 8 new recruits to have the resources to immediately develop their research programs. Since their arrival at MSK, these 8 investigators have received $23.8M in peer-reviewed funding and produced over 25 manuscripts from their laboratories. Funds requested to support cross-disciplinary pilot projects involving PSR and other Center programs supported 16 projects, covering the broad spectrum of areas of population research that characterize the PSR Program, with multiple awards in each of PSR?s major programmatic themes: 1) cancer etiology and risk; 2) health behavior and symptom control; and 3) health care delivery, access and disparities. The projects were multidisciplinary as a requirement, and in many cases creative cross-disciplinary interactions were formed, matching population scientists with basic laboratory investigators or clinical investigators. Results have been exciting, with 3 of our junior investigators receiving their first NIH grants as a result of the pilot funds provided by this program. To date, 8 peer-reviewed grants have been awarded stemming from the research conducted in these pilot projects (4 NCI, 2 other NIH, 2 ACS). The total direct cost from these grants is $8,816,229. Building on the success in the current grant period, the Center proposes to continue its program in PSR Pilot Project Funding. We also propose a second faculty recruitment initiative to support the recruitment and integration of faculty with expertise in computational biology. This initiative will build on recent, strategic infrastructure investments in computational biology made by MSK.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Kaley, Thomas; Touat, Mehdi; Subbiah, Vivek et al. (2018) BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study. J Clin Oncol :JCO2018789990
Kiesgen, Stefan; Chicaybam, Leonardo; Chintala, Navin K et al. (2018) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. J Thorac Oncol 13:16-26
Pak, Linda M; Kemeny, Nancy E; Capanu, Marinela et al. (2018) Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. J Surg Oncol 117:634-643
Kunimoto, Hiroyoshi; Meydan, Cem; Nazir, Abbas et al. (2018) Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer Cell 33:44-59.e8
Lee, Sangkyu; Kerns, Sarah; Ostrer, Harry et al. (2018) Machine Learning on a Genome-wide Association Study to Predict Late Genitourinary Toxicity After Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys 101:128-135
Speranza, Giovanna; Anderson, Larry; Chen, Alice P et al. (2018) First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile. Invest New Drugs 36:230-239
Pratt, Edwin C; Shaffer, Travis M; Zhang, Qize et al. (2018) Nanoparticles as multimodal photon transducers of ionizing radiation. Nat Nanotechnol 13:418-426
Rusch, Valerie W (2018) Has Reconstruction of the Central Airways Been Transformed?: From Aorta to Trachea. JAMA 319:2177-2178
Francini, Edoardo; Yip, Steven; Ahmed, Shubidito et al. (2018) Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clin Genitourin Cancer 16:130-134
Fleshner, Katherine; Carlsson, Sigrid V (2018) The USPSTF screening recommendation: a swinging pendulum. Nat Rev Urol 15:532-534

Showing the most recent 10 out of 8799 publications